SUMMARY The effect of pirenzepine on 24 hour intragastric acidity was studied in 10 healthy volunteers using ambulatory 24 
placebo in the treatment of duodenal ulcer disease. 3 The drug has been shown to reduce gastric volume secretion,4 5 but the effect of chronic ingestion on gastric acidity has not been evaluated in man. The aim of the present study was therefore to evaluate the effect of a high and a low oral dose of pirenzepine on 24 hour gastric acidity in healthy subjects. Gastric pH was monitored by means of continuous electrode measurements which has been validated in our laboratory. 6 The day to day reproducibility of the method was tested in a series of repeat measurements during placebo treatment.
Methods

SUBJECTS
Ten healthy volunteers (six men, four women, median age 25 years) participated in the study.
Informed consent was obtained in all cases, and the protocol was approved by the local ethical committee.
Gastric pH was measured by miniature glass electrodes (Radiometer Copenhagen GK282C) connected to a pH meter with digital read-out (Metrohm E 602, T°:37°C) and an analogical recorder (Tarcan W+W, chosen speed:12 cm/h). Before and after each 24-hour test, the electrodes were calibrated with commercial buffer solutions (Ingold pH 7, pH 4-01 and pH 1-679). The mean hydrogen ion activity is shown in the Figure (upper graph) . Individual values for day and night times are given in the Table. As compared with placebo, the mean 24 hour H+ activity was reduced by 19% and 29% under the two regimens of 75 and 150 mg of pirenzepine, respectively (p<0O001). The reduction of intragastric H+ activity during the day time was not significant (4% and 12% respectively, p>0l10). During the night time, the reduction was statistically significant (26% and 36% respectively, p<0.001). A dose of 150 mg of pirenzepine per day was more effective than a dose of 75 mg, but the difference was only significant '(p<0-05) at night. The pH threshold curves as shown in the figure are similar with placebo and with the two doses of pirenzepine for the whole 24 hour period (lower graph).
SERUM PIRENZEPINE CONCENTRATIONS
The plasma concentrations of pirenzepine correlated well with the ingested doses (mean±SEM, ten subjects): with placebo, they were always under the limit of detectability of the method; with pirenzepine 75 mg/d, the plasma concentrations were 27+3-7, 34±5-5 and 26±2-7 ng/ml at 8 am, 2 pm and 8 pm respectively; with pirenzepine 150 mg/d, the corresponding values were 53±4-3, Pirenzepine 75 mg twice daily:
*-72±9 0 and 50±4-6 ng/ml respectively. No correlation was found between the effect of pirenzepine on acidity and the serum concentrations.
Discussion
In the present study we have evaluated the effect of long term administration of pirenzepine on gastric acidity using a new method of continuous intragastric pH-metry. We have recently validated this method and its good reproducibility was again shown in repeat placebo tests in seven volunteers (Table) . Hydrogen ion activity during placebo treatment was, on average, 30-40 mmol/l during the day and much higher -that is, 60-70 mmol/l, at night. Similar findings were reported by others.11 Pirenzepine had only a small effect on intragastric pH. Even a high dose of 150 mg which may cause anticholinergic side effects, reduced nocturnal acidity by only 36% and had no measurable effect on diurnal acidity. It is surprising that such a small reduction of acid concentration may be sufficient for the acceleration of ulcer healing. It might be argued that the effect of pirenzepine decreases over time and might be higher on the first than on the seventh day of treatment. Pirenzepine is, however, given to ulcer patients at a fixed dose during several weeks. Thus, the effect seen in the present study is more representative of what happens in a clinical setting than in studies where the drug is given only on one day. It might further be argued that pirenzepine may reduce gastric volume output even in the absence of an effect on hydrogen ion activity4 5 and that this volume effect may, on its own, reduce duodenal bulb acidity. Pirenzepine has, however, also been shown to accelerate gastric ulcer healing. 12 Therefore, it is uncertain whether there is a direct relationship between the extent of secretory inhibition and therapeutical efficacy of a drug.
Future studies with drugs which almost completely inhibit acid production' 14 
